Cibus, Inc. (NASDAQ: CBUS)

Cibus, Inc., previously known as Calyxt, Inc., operates in the synthetic biology industry, a sector that has experienced significant growth in recent years. Based in Minnesota, USA, the company leverages its PlantSpring technology platform to engineer plant metabolism and produce innovative, high-value, and sustainable materials and products. Cibus' main business activities revolve around the development and licensing of its technology platform, as well as the production and sale of plant-based chemistries and plant traits.

The company generates revenue primarily through its PlantSpring technology platform, which is used to create a variety of products. These products include plant-based proteins, colorants, advanced materials, pharma-grade products, and other compounds. Cibus' primary customers are in the cosmeceutical, nutraceutical, and pharmaceutical industries. The company's unique technology platform enables it to produce plant-based chemistries from plant species, including rare or undomesticated species, in a more robust and sustainable manner compared to other production methods.

Cibus' product portfolio includes plant-based proteins, colorants, advanced materials, pharma-grade products, and other compounds. Its plant-based proteins serve as a sustainable alternative to traditional protein sources and can be used in various applications, such as food, cosmetics, and pharmaceuticals. The company's colorants are suitable for use in food, cosmetics, and pharmaceuticals, offering a sustainable alternative to traditional colorants derived from animals or synthetic sources. Cibus' advanced materials can be used in textiles, packaging, and construction, providing a sustainable alternative to traditional materials derived from fossil fuels or non-renewable sources.

Pharma-grade products, including vaccine adjuvants and antibiotics, are also part of Cibus' offerings, produced using its proprietary technology platform. These products provide a sustainable alternative to traditional pharmaceutical products derived from animals or synthetic sources. Additionally, the company has developed a range of other plant-based compounds, including flavorings, fragrances, and nutraceuticals. These compounds offer a sustainable alternative to traditional compounds derived from animals or synthetic sources.

Cibus holds a strong intellectual property portfolio with over 160 patents and patent applications worldwide. The company has licensed technology from other parties, including Cellectis and the University of Minnesota. Cibus' competitive advantage lies in its exclusive focus on plant-based solutions and its proprietary technology platform, which has the potential to revolutionize how the world uses plants. Key competitors in the synthetic biology industry include Intrexon, Synthetic Genomics, and Codexis.